Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
Lori M. Minasian(National Cancer Institute), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Vaia Vlamis, Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Madhu Mazumdar(Memorial Sloan Kettering Cancer Center), Louis Gluck(Yale University)
Cited by 292
Related Papers
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
|UCL Discovery (University College London)|1997|1k